Literature DB >> 3080373

Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

S MacIntyre, T McVeigh, P Owen.   

Abstract

The Pseudomonas aeruginosa polyvalent vaccine PEV and its 16 constituent monovalent extracts from International Antigenic Typing System serotypes 1 through 13 and 15 through 17 (J. J. Miler, J. F. Spilsbury, R. J. Jones, E. A. Roe, and E. J. L. Lowbury, J. Med. Microbiol. 10:19-27, 1977) were subjected to biochemical analysis and to detailed immunochemical analysis with rabbit anti-PEV immunoglobulins. The results of chemical analysis, of analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis performed in conjunction with silver staining, and of analysis by crossed immunoelectrophoresis, sodium dodecyl sulfate-polyacrylamide gel-crossed immunoelectrophoresis, and Western blotting showed clearly that lipopolysaccharide was a major constituent of each monovalent extract and that it was probably the dominant antigen present in at least 15 of the 16 monovalent extracts. A 16.2-kilodalton protein, which was pronase resistant and nonsedimentable at 105,000 X g and which appeared to be biochemically and antigenically unrelated to pili, was a common although minor antigen for all extracts. Several other proteins, some of outer membrane origin, were also detected in unformalinized extracts, but these were also minor antigenic constituents of the vaccine. Neither pilin nor flagellin appeared to be major protein constituents of tested monovalent extracts, although anti-flagella antibodies could be demonstrated in rabbit anti-PEV by Western blotting. Preliminary analysis by crossed immunoelectrophoresis of serum raised in volunteers to PEV also indicated the presence therein of antibodies to lipopolysaccharide antigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080373      PMCID: PMC262404          DOI: 10.1128/iai.51.2.675-686.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Effects of a glycopolypeptide from the slime of P. aeruginosa on phagocytosis by mouse macrophages.

Authors:  M Nadaud
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1983-07

2.  Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.

Authors:  M Pollack; G B Pier; R K Prescott
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

3.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.

Authors:  H E Gilleland; M G Parker; J M Matthews; R D Berg
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

4.  Further purification and characterization of high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; M Cohen; H Jennings
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

5.  Antibody response of infected mice to outer membrane proteins of Pseudomonas aeruginosa.

Authors:  R C Hedstrom; O R Pavlovskis; D R Galloway
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

6.  Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  Ethylenediaminetetraacetate-extractable protein-lipopolysaccharide complex of Pseudomonas aeruginosa: characterization of protein components.

Authors:  R C Hedstrom; R K Schockley; R G Eagon
Journal:  J Bacteriol       Date:  1981-12       Impact factor: 3.490

8.  Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis.

Authors:  J S Lam; L M Mutharia; R E Hancock; N Høiby; K Lam; L Baek; J W Costerton
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

9.  Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies.

Authors:  L M Mutharia; R E Hancock
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains.

Authors:  R P Darveau; R E Hancock
Journal:  J Bacteriol       Date:  1983-08       Impact factor: 3.490

View more
  10 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; R Lucken; P Owen
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Production of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa.

Authors:  J S Lam; L A MacDonald; M Y Lam
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

4.  Structural elucidation of the lipopolysaccharide core region of the O-chain-deficient mutant strain A28 from Pseudomonas aeruginosa serotype 06 (International Antigenic Typing Scheme).

Authors:  H Masoud; I Sadovskaya; T de Kievit; E Altman; J C Richards; J S Lam
Journal:  J Bacteriol       Date:  1995-12       Impact factor: 3.490

5.  Identification, immunochemical characterization, and purification of a major lipoprotein antigen associated with the inner (cytoplasmic) membrane of Escherichia coli.

Authors:  H Doherty; H Yamada; P Caffrey; P Owen
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

Review 6.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

7.  Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa.

Authors:  J S Lam; L A MacDonald; M Y Lam; L G Duchesne; G G Southam
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

8.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  G B Pier; D Desjardins; T Aguilar; M Barnard; D P Speert
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

Review 9.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

Review 10.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.